TrialThe Lancet. Neurology2022

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.

Elia M Pestana Knight et al.PubMed ↗Publisher ↗

No numbers read from the abstract.